Bajaj Auto Ltd on Wednesday said it will set up an electric vehicle manufacturing facility at Akurdi in Pune with an investment of Rs 300 crore.

The facility, for which the work has already commenced, will have the capacity to produce 5,00,000 Electric Vehicles (EVs) per annum and cater to both domestic and exports markets, the company said in a release.

The Drug Controller General of India (DCGI) has given approval to the Hyderbad-based pharmaceutical company Biological E to conduct phase 3 clinical trials of its COVID-19 vaccine Corbevax as a booster dose, said sources.

After detailed deliberation, the Subject Expert Committee recommended granting permission to conduct proposed Phase 3 clinical trials, sources told ANI.

Seven new cases of Omicron variant of COVID-19 have been reported in Hyderabad during the last 24 hours, said the state government on Tuesday.

With this, the tally of Omicron cases in Telangana has reached 62.

As per the state government, 13 of these 62 patients have recovered and have been discharged from the state-run TIMS hospital.

Shares of C E Info Systems (MapmyIndia) hit a new high of Rs 1,774.80, on rallying 10 per cent on the BSE in Wednesday’s intra-day trade. The stock has surged 22 per cent in last two trading sessions after having made a strong debut last week.

With the past two-day rally, MapmyIndia now commands a whopping 72 per cent premium to its issue price of Rs 1,033 per share on the BSE. The company had made its stock market debut on December 21, 2021.

Supriya Lifescience made a strong debut on the bourses on Tuesday. The stock got listed at Rs 425 - a gain of 55 per cent above its issue price. The stock gave up some of its listing gains and ended the session at Rs 390 - a 42.5 per cent premium to its issue price. After listing, the company commands a market capitalisation of Rs 3,141 crore.

The initial public offering (IPO) of Supriya Lifescience was subscribed 74x. The institutional portion was subscribed 33x, the wealthy investor portion 166x, and the retail investor portion 57x.

As part of its ambitious charging infrastructure goal, Ola Electric will install more than 4,000 charging points for its electric scooters across cities in next year.

In a tweet, Bhavish Aggarwal, Founder and CEO, Ola, said that Hypercharger roll out has begun across cities.


At key BPCL pumps as well as residential complexes. 4000+ points up through next year. We're installing across India and will make them operational in 6-8 weeks. Will be free for use till end June 22 for all customers, he said in a tweet late Tuesday.

Hyundai Engineering announced on the 28th that it has completed construction of GTL (Gas-to-Liquid) plant worth $2.62 billion (about 3.1 trillion won) in Uzbekistan.

Hyundai Engineering held a completion ceremony on the 25th (local time). At the ceremony, officials from the Uzbekistan government, including President Shavkat Mirziyoyev, Prime Minister Abdulla Aripov, Energy Minister Alisher Sultanov, and Korean officials, including Hyundai Engineering CEO Kim Chang-hak, attended.

IndusInd Bank has signed an agreement with the National Payments Corporation of India (NPCI) for offering real-time cross-border remittances through Unified Payments Interface (UPI).

IndusInd Bank has become the first Indian bank to go live on UPI for cross-border payments/NRI remittances. Under this arrangement, Money Transfer Operator (MTO) partners of IndusInd Bank would use the bank's channel to connect with NPCI's UPI payment systems for validation and cross-border payment settlement into beneficiary accounts.

The Sebi on Tuesday clarified that Sahara is yet to fully deposit the money ordered by the Supreme Court in August 2012 and that the group has so far given only around Rs 15,000 crore while the total amount due to be deposited is Rs 25,781 crore.

Quoting Sebi's FY21 annual report, a media report said the regulator had paid back only Rs 129 crore to bondholders and that it was maintaining an escrow account with over Rs 23,000 crore.

Sun Pharma on Tuesday said its subsidiary has received emergency use authorisation (EUA) from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of MSD and Ridgeback's antiviral drug molnupiravir under the brand name Molxvir in India.

Earlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply a generic version of molnupiravir in over 100 low and middle-income countries (LMICs) including India.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.